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with PD ( 2 = 5.14, 1 df, 2 P = 0.02), suggesting a tendency to heterozygosity in PD (Table 1) .
To date, most of the efforts to elucidate the genetic factors underlying PD have been focused on genes whose products are involved in its pathophysiology or that could mediate the biological effects caused by panicogenic agents. Changes in the expression or function of NTRK3 may alter synaptic plasticity through the change of local trophic support. This could possibly cause the abnormal release rates of certain neurotransmitters, like NA, in target areas that lead to the alteration of the individual's arousal threshold. The SNP we found more frequently in the PD sample is located in the putative promoter region of the gene, giving support to the hypothesis that the alteration of the normal amounts of messenger could participate in the pathophysiology of PD. Since most samples used in our study also have DUP25, the 5′ UTR SNP described above might be one of several genetic factors that contribute to modify the development and severity of panic disorder. Serotonin neurotransmission is involved in the regulation of mood, sleep, vigilance, memory and learning, feeding and sexual behaviour. All those functions have found to be altered to varying extents in depressed patients. The serotonin 1A receptor has been postulated as playing a major role in anxiety, depression and other psychiatric disorders. 1 This receptor regulates the firing of serotonergic neurones and mediates the action of non-serotonergic neurones prominently in the limbic regions.
Analysis of structural polymorphisms and C-
2 Moreover, the 5-HT 1A receptor has been hypothesised to have an important role in the modulation of clinical response to antidepressant drugs. Long-term treatment with SSRIs desensitises the somatodendritic 5-HT 1A receptors leading to an enhanced release of serotonin. 3 In addition, it has been reported that a combination of SSRI drugs and blockade of these receptors may accelerate the therapeutic efficacy in depressive patients. 4 All these facts lead us to consider the 5-HT 1A receptor gene as a good candidate gene for association studies in major depression. The 5-HT 1A receptor gene (chromosome 15q11) is intronless and codes a 422-amino acid protein. 5 A number of low frequency single nucleotide polymorphisms (SNPs) have been described on this gene. 6, 7 Previous association studies investigating the putative role of the 5-HT 1A receptor gene in schizophrenia and major depression have failed to demonstrate any relation between these polymorphisms and the disorders. [6] [7] [8] Recently, a novel and relatively common polymorphism (C-1018G) that may provide useful information on the involvement of this receptor gene in mental disorders, has been described on the promoter region of the 5-HT 1A receptor gene. 9 We hypothesised that genetic variation in the 5-HT 1A receptor gene could be involved in the aetiology of major depression or in clinical features related to this complex disorder. To test this hypothesis, we have performed individual association studies of the novel promoter region polymorphism C-1018G and three previously reported structural polymorphisms (Ile28Val, Asp272Gly, and Pro16Leu) in a large sample of depressive patients.
Two hundred and forty-nine unrelated patients (64 men and 185 women; mean age: 46.6 ± 10.09) with major depression from the Mental Health Service of the Eixample District (Barcelona, Spain) were included in the study. Major depression was diagnosed according to DSM-IV 10 criteria and the Spanish version of the Structural Clinical Interview for DSM-III-R (SCID) was used for this purpose.
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One hundred and seventy healthy individuals (89 males and 81 females; mean age: 38.2 ± 10.35) were recruited as controls. Patients and control subjects were matched to the same geographic area through the birthplace of their grandparents. Both patients and controls provided written informed consent prior to their inclusion in the study. Genomic DNA was extracted from blood samples using standard techniques. Four polymorphisms were analysed: (i) Asp272Gly (coding region); (ii) Ile28Val (extracellular amino terminal domain); (iii) Pro16Leu (extracellular amino terminal domain); and (iv) C-1018G (promoter region). The three first polymorphisms were genotyped according to the protocols described previously. 6, 7 New mutagenic primers and PCR conditions were designed for the genotypic characterisation of the C-1018G polymorphism. PCR amplification was performed with the following primers: 5ЈTGG AAG AAG ACC GAG TGT GTC TAC 3Ј and 5ЈTTC TCC CTG GGA GAG TAA GGC TGG 3Ј. The reaction mix contained 100 ng of DNA, 1.5 mM of MgCl 2 , 200 M of each dNTP, 1 M of primer and 0.5 U of BioTaq Polymerase (Bioline, UK) in a final volume of 25 l. Thirty-five cycles of 45 s at 95°C, 45s at 56°C and 45 s at 72°C were performed, followed by a final step of 10 min at 72°C. A final PCR product of 182 bp was obtained. PCR products were digested using 4 U of Hpy CH4IV restriction enzyme (New England BioLabs) and the digested fragments were separated on 4% agarose gels. The restriction pattern was: C-1018 182 bp; G-1018 158 bp and 24 bp. Randomised individuals were re-tested for their genotype, confirming that enzyme digestion was complete and the digestion pattern was reproducible.
Genotype frequencies were in Hardy-Weinberg equilibrium in patients ( 2 = 0.0, df = 2, P = 1.0) and controls ( 2 = 0.96, df = 2, P = 0.62). Association studies were performed using 2 tests to compare cases and controls and to confirm the presence or absence of allele or genotype associations. No statistical comparison can be performed with the coding region polymorphisms Gly272Asp, Ile28Val, Leu16Pro, as a result of their low frequencies in our Spanish samples. Only two control individuals were found to be heterozygous for the Ile28Val polymorphism. No subjects carrying the rare allele of the Gly272Asp and Leu16Pro polymorphisms were found.
When we analysed genotype and allele distribution for the C-1018G polymorphism, no differences were Molecular Psychiatry found between patients with major depression and controls (genotype comparison; 2 = 1.24, df = 2, P = 0.53; allele comparison; 2 = 0.00, df = 1, P = 0.97) (see Table 1 for genotype and allele frequencies). The combined study group had more than 80% power to detect an allelic or genotypic association (odds ratio Ն 1.8) given the C-1018G allele frequencies in the general population.
Seasonal course, melancholy, suicidal behaviour or presence of psychotic symptoms were also analysed taking into account that previous studies have related genetic variation in other serotonergic genes such as SERT (serotonin transporter) or 5-HT 2A with these clinical features [12] [13] [14] . However, no association was found between the 5-HT 1A polymorphisms and those clinical variables in our sample (data not presented).
Despite the fact that no positive results have been found in our study, it is possible that the 5-HT1A receptor gene plays a minor role in major depression which can not be detected due to our sample size. In that case, a much larger study group would be required to establish the possible gene effect. Certainly, the 5-HT1A receptor is likely to have some consequences for mental disorders due to the implication in the actions of antidepressant clinical treatments as well as in the control of the intersynaptic serotonin release. Although the genetic variants found in the 5-HT 1A gene are not determinant on the receptor function or action, this neither excludes this receptor as an important factor in the aetiology of major depression, nor confirms it.
Summarising, our results suggest that genetic variation in the 5-HT 1A is not a major risk factor for major depression or clinical features related to the disease. 
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